Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted positive clinical trial results for zerlasiran and divesiran, revenue growth, and an extended cash runway. However, the termination of the Hansoh Pharma collaboration and the delay of the zerlasiran Phase 3 study due to the need for a partner were significant challenges mentioned.Company Guidance
Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Divesiran Phase 1 Success and Phase 2 Progress
The SANRECO’s Phase 1 study of divesiran showed positive results, eliminating the need for phlebotomy in all well-controlled patients. Phase 2 study dosing has started, and the European Commission has granted divesiran Orphan Drug Designation for PV.
Revenue Growth
The company recorded $43.3 million in revenues for 2024, an increase of $11.7 million from 2023, largely due to collaboration arrangements utilizing the siRNA platform.
Extension of Cash Runway
By delaying the Phase 3 study of zerlasiran until a partner is secured, the company has extended its projected cash runway into 2027.
DE:XRP2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:XRP2 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €5.95 | €6.00 | +0.84% |
Mar 05, 2026 | €4.60 | €4.70 | +2.17% |
Nov 06, 2025 | €5.40 | €5.15 | -4.63% |
Aug 07, 2025 | €4.60 | €4.30 | -6.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Silence Therapeutics (DE:XRP2) report earnings?
Silence Therapeutics (DE:XRP2) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Silence Therapeutics (DE:XRP2) earnings time?
Silence Therapeutics (DE:XRP2) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Silence Therapeutics stock?
The P/E ratio of Silence Therapeutics is N/A.
What is DE:XRP2 EPS forecast?
DE:XRP2 EPS forecast for the fiscal quarter 2026 (Q2) is -0.12.